Clinical trials: Community Acquired Pneumonia, Severe
Infectious Pneumonia, Severe COVID-19
Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia
Primary objective: To compare the efficacy of reparixin vs. placebo in the proportion of patients dead or requiring IMV (or ECMO) by Day 28.
- Trial name
- NCT05254990
- Testing
- Reparixin
- Where
- 74 sites in United States, Argentina and 5 more
- Volunteers
- 414 people
- Sponsor
- Dompé Farmaceutici S.p.A
Severe Community-acquired Pneumonia (sCAP)
Appropriateness of Antibiotic Combination Therapy for Severe Community-acquired Pneumonia in South Korea
This study aims to provide high-level evidence for appropriate empirical antibiotic use tailored to the clinical reality in Korea by conducting a randomized controlled trial comparing monotherapy with piperacillin/tazobactam and…
- Trial name
- ACTSCAP (NCT06977347)
- Testing
- Piperacillin/Tazobactam, Piperacillin/tazobactam + Levofloxacin
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- CHOSEOK YOON
Pneumonia, Child
Predicting Severe Outcomes Among Children Hospitalized With Community-acquired Pneumonia
In this study, investigators aimed to develop and validate a risk score to predict severe outcomes (e.g., mortality and ICU admission) in children who were admitted to the Children's Hospital of Fudan University between 2017 and…
- Conditions
- Pneumonia, Child, Prognosis
- Trial name
- NCT05744609
- Testing
- exposures of interest: epidemiological data, clinical characteristics, laboratory data, and chest radiographic reports
- Where
- China
- Volunteers
- 6,000 people
- Sponsor
- Children's Hospital of Fudan University
Community-acquired Pneumonia, Hospital-acquired Pneumonia
Diagnostic Performance and Impact of a Multiplex PCR Pneumonia Panel in ICU Patients With Severe Pneumonia.
The objective of this study is to assess the diagnostic performance of multiplex respiratory PCR (PCR-RM) compared to standard microbiological tests and its potential impact on the early adaptation of antibiotic treatment in…
- Conditions
- Community-acquired Pneumonia, Hospital-acquired Pneumonia, Ventilator Associated Pneumonia
- Trial name
- NCT05624684
- Testing
- Multiplex respiratory PCR
- Where
- Morocco
- Volunteers
- 210 people
- Sponsor
- Avicenna Military Hospital
Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum
Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS)
This Phase 2 study tests whether adding two immune therapies - nogapendekin alfa-inbakicept (NAI) and off-the-shelf iNKT cell infusions - to standard care can safely help critically ill adults with severe community-acquired…
- Conditions
- Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum, Sepsis, Lymphopenia / Immunoparalysis in Critically Ill Adults
- Trial name
- NCT07492888
- Testing
- Nogapendekin Alfa-Inbakicept (NAI), Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797)
- Sponsor
- ImmunityBio, Inc.
Pneumonia
A Study to Compare the Safety and Effectiveness of 2 Doses of Levofloxacin Given for Different Time Periods in Patients With Pneumonia
The purpose of this study is to evaluate the effectiveness and safety of two antibiotic regimens in the treatment of community-acquired pneumonia in non-hospitalized adult patients.
- Trial name
- NCT00236821
- Testing
- levofloxacin
- Volunteers
- 530 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Adenovirus Infections, Human
Adaptive RCT of Corticosteroids for Severe Adenovirus Pneumonia in Adults
Severe community-acquired pneumonia caused by adenovirus (hereafter referred to as severe adenovirus pneumonia) is one of the common forms of severe community-acquired pneumonia in immunocompetent adults.
- Trial name
- CAPSTONE-AD (NCT07152600)
- Testing
- Saline (0.9%, sterile, for infusion), low dose Methylprednisolone, Moderate dose Methylprednisolone
- Volunteers
- 262 people
- Sponsor
- Qingyuan Zhan
Community Aquired Pneumonia
Study to Evaluate Two Diagnostic Strategies for the Treatment of Severe Community Acquired Pneumonia (SCAP)
Main hypothesis: microbiological diagnossis off severe community acquired pneumonia can be performed by non invasive or semi invasive microbiological tools, semi invasive tools including protected distal bronchial samplings by…
- Trial name
- NCT00308659
- Testing
- FOB protected distal microbiological samplings
- Where
- France
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Community Acquired Pneumonia
Community-Acquired Pneumonia : Evaluation of Corticosteroids
Mortality of severe Community-Acquired Pneumonia (CAP) has not declined over time and is between 25 and 30% in sub-groups of patients.
- Trial name
- CAPE_COD (NCT02517489)
- Testing
- Hydrocortisone
- Where
- 32 sites in France
- Volunteers
- 952 people
- Sponsor
- University Hospital, Tours
Respiratory Infection, Pneumonia
Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia
The main objectives of the trial are to assess the efficacy and safety of trimodulin as adjunctive treatment to standard of care (SoC) compared to placebo plus SoC in adult hospitalized subjects with non-severe community-acquired…
- Conditions
- Respiratory Infection, Pneumonia, Community-acquired Pneumonia, Acute Respiratory Distress Syndrome
- Trial name
- TRICOVID (NCT05531149)
- Testing
- Trimodulin
- Where
- 64 sites in Argentina, Austria and 12 more
- Volunteers
- 107 people
- Sponsor
- Biotest
Community Acquired Pneumonia
Corticosteroid Therapy for Severe Community-Acquired Pneumonia
The purpose of the present study is to assess the efficacy of methylprednisolone as an adjuvant therapy in patients with severe community-acquired pneumonia (CAP) (PSI 4-5).
- Trial name
- NCT02552342
- Testing
- methylprednisolone, Normal saline
- Where
- China
- Volunteers
- 610 people
- Sponsor
- Peking Union Medical College Hospital
Community-acquired Pneumonia
Use of a Rapid Diagnostic Test for Antibiotic De-escalation in Severe Community Acquired Pneumonia
The purpose of this study is to conduct an open-label step-wedge pilot clinical trial to compare an antibiotic strategy based on routine use of a novel rapid diagnostic test to usual care in critically ill adults with severe…
- Trial name
- BioFire (NCT04781829)
- Testing
- BioFire Pneumonia Panel
- Sponsor
- Northwestern University
Pneumonia
Efficacy and Safety of Sequential IV/PO Moxifloxacin in Comparison to IV Levofloxacin Plus IV Ceftriaxone Followed by PO Levofloxacin, in the Treatment of Patients With Community-acquired Pneumonia
Sequential therapy with intravenous to oral moxifloxacin, was tested at 69 study centres in 17 countries to determine if this treatment regimen is safe and effective in treating hospitalized adult patients with community-acquired…
- Trial name
- NCT00431678
- Testing
- Avelox (Moxifloxacin, BAY12-8039), Levofloxacin + Ceftriaxone
- Where
- 95 sites in Argentina, Belgium and 16 more
- Volunteers
- 738 people
- Sponsor
- Bayer
Severe Community-acquired Pneumonia (sCAP)
Epidemiology and Current Practices in Severe Community-Acquired Pneumonia
The goal of this observational study is to learn more about severe community-acquired pneumonia (sCAP) in adults who need hospital or intensive care.
- Trial name
- PLENITUDE (NCT07301099)
- Where
- Colombia
- Volunteers
- 2,588 people
- Sponsor
- Universidad de la Sabana
Community-Acquired Pneumonia
Customized Antibiotic Treatment Duration Among Hospitalized Patients With Moderately Severe Community-Acquired Pneumonia
The primary objective of the study is to evaluate if the efficacy of an experimental strategy on antibiotic treatment duration based on stopping treatment when stability criteria are reached after at least 48 h of treatment, is…
- Trial name
- CAT-CAP (NCT05903352)
- Testing
- Stop antibiotic, Continue the antimicrobial treatment
- Where
- France
- Volunteers
- 328 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
ARDS (Acute Respiratory Distress Syndrome)
Time-controlled Adaptive Ventilation (TCAV) Compared With Conventional Ventilation in Patients With Moderate-to-severe Acute Respiratory Distress Syndrome (ARDS) Secondary to Community-acquired Pneumonia
ARDS is a pathology with mortality rates reaching 40%. Invasive ventilation, the cornerstone of ARDS management, leads to "ventilation-induced lung injury" (VILI).
- Trial name
- EARLY-TCAV (NCT07679802)
- Testing
- Invasive ventilation with the Time-controlled Adaptative Ventilation settings applied to the Airway Pressure Release Ventilation mode, Volume Control
- Where
- France
- Volunteers
- 56 people
- Sponsor
- Central Hospital, Nancy, France
Community-acquired Pneumonia
Monotherapy Versus Bitherapy in Non-severe Hospitalized Community-acquired Pneumonia
The purpose of this study is to determine whether a monotherapy with a Beta-Lactam is not inferior to an association of a Beta-Lactam and a macrolide in treating adult patients with community-acquired pneumonia.
- Trial name
- BICAP (NCT00818610)
- Testing
- Beta lactam (amoxicillin / clav. acid OR cefuroxime), Beta-lactam (amoxicillin / clav. acid OR cefuroxime) AND macrolide (clarithromycin)
- Where
- 6 sites in Switzerland
- Volunteers
- 601 people
- Sponsor
- Swiss National Fund for Scientific Research
Pneumonia
Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia
The purpose of this study is to determine whether tifacogin is effective and safe in the treatment of patients with severe community-acquired pneumonia.
- Trial name
- NCT00084071
- Testing
- Tifacogin
- Where
- 150 sites in United States, Argentina and 16 more
- Volunteers
- 2,136 people
- Sponsor
- Novartis Pharmaceuticals
Community-acquired Pneumonia
Twice Daily Treatment With Amoxicillin for Non-severe Community Acquired Pneumonia.
The aim of this study will be to evaluate whether a twice-daily antibiotic regimen is non-inferior to a thrice-daily regimen for the treatment of non-severe community acquired pneumonia in children presenting at a paediatric…
- Trial name
- NCT03031210
- Testing
- Amoxicillin
- Where
- Canada
- Volunteers
- 1,370 people, healthy volunteers welcome
- Sponsor
- St. Justine's Hospital
Community-acquired Pneumonia, Covid19
Study of a Possible Respiratory Degradation Prognosis Caused by Biomarkers in Severe Forms of COVID-19 Pneumonia
Respiratory infection with the SARS-CoV2 virus is associated with a major risk of viral pneumonia that can lead to respiratory distress requiring resuscitation.
- Trial name
- LPSARS2 (NCT04505605)
- Testing
- Blood samples
- Where
- 2 sites in France
- Volunteers
- 20 people
- Sponsor
- Fondation Hôpital Saint-Joseph